Characterization of Remitting and Relapsing Hyperglycemia in Post-Renal-Transplant Recipients

Background Hyperglycemia following solid organ transplant is common among patients without pre-existing diabetes mellitus (DM). Post-transplant hyperglycemia can occur once or multiple times, which if continued, causes new-onset diabetes after transplantation (NODAT). Objective To study if the first and recurrent incidence of hyperglycemia are affected differently by immunosuppressive regimens, demographic and medical-related risk factors, and inpatient hyperglycemic conditions (i.e., an emphasis on the time course of post-transplant complications). Methods We conducted a retrospective analysis of 407 patients who underwent kidney transplantation at Mayo Clinic Arizona. Among these, there were 292 patients with no signs of DM prior to transplant. For this category of patients, we evaluated the impact of (1) immunosuppressive drugs (e.g., tacrolimus, sirolimus, and steroid), (2) demographic and medical-related risk factors, and (3) inpatient hyperglycemic conditions on the first and recurrent incidence of hyperglycemia in one year post-transplant. We employed two versions of Cox regression analyses: (1) a time-dependent model to analyze the recurrent cases of hyperglycemia and (2) a time-independent model to analyze the first incidence of hyperglycemia. Results Age (P = 0.018), HDL cholesterol (P = 0.010), and the average trough level of tacrolimus (P<0.0001) are significant risk factors associated with the first incidence of hyperglycemia, while age (P<0.0001), non-White race (P = 0.002), BMI (P = 0.002), HDL cholesterol (P = 0.003), uric acid (P = 0.012), and using steroid (P = 0.007) are the significant risk factors for the recurrent cases of hyperglycemia. Discussion This study draws attention to the importance of analyzing the risk factors associated with a disease (specially a chronic one) with respect to both its first and recurrent incidence, as well as carefully differentiating these two perspectives: a fact that is currently overlooked in the literature.

[1]  G. Viberti,et al.  Diabetogenic effect of cyclosporin. , 1987, British medical journal.

[2]  M. Arias,et al.  New-onset diabetes after kidney transplantation: risk factors. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  M. Diamant,et al.  Steroid diabetes: from mechanism to treatment? , 2014, The Netherlands journal of medicine.

[4]  D. Hricik,et al.  Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. , 1991, Transplantation.

[5]  P. Marchetti.  New-onset diabetes after transplantation. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  T. Takács,et al.  Functional and histopathologic changes in renal transplant patients with new-onset diabetes and dyslipidemia. , 2011, Transplantation proceedings.

[7]  A. Henning,et al.  New‐Onset Diabetes After Transplantation: Results From a Double‐Blind Early Corticosteroid Withdrawal Trial , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  S. Korom,et al.  The effect of low-dose Continuous Erythropoietin receptor activator in an experimental model of acute Cyclosporine A induced renal injury. , 2011, European journal of pharmacology.

[9]  H. Ye,et al.  Hyperglycemia Induced by Glucocorticoids in Nondiabetic Patients: A Meta-Analysis , 2014, Annals of Nutrition and Metabolism.

[10]  J.H. Cho,et al.  Effect of transient post-transplantation hyperglycemia on the development of diabetes mellitus and transplantation outcomes in kidney transplant recipients. , 2015, Transplantation proceedings.

[11]  J. Davidson,et al.  New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. , 2004, Diabetes care.

[12]  M. Vranic,et al.  The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Pascual,et al.  Immunosuppression and Post-transplant Hyperglycemia. , 2015, Current diabetes reviews.

[14]  J. Rakela,et al.  New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database , 2013, Journal of transplantation.

[15]  S. Goh,et al.  Incidence and risk factors for development of new-onset diabetes after kidney transplantation. , 2011, Annals of the Academy of Medicine, Singapore.

[16]  D. Owens,et al.  Insulin Resistance Indexes in Renal Transplant Recipients Maintained on Tacrolimus Immunosuppression , 2010, Transplantation.

[17]  L. Pączek,et al.  Posttransplantation diabetus mellitus under calcineurin inhibitor. , 2003, Transplantation proceedings.

[18]  W. Knowler,et al.  Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[19]  Raymond Vanholder,et al.  New-Onset Diabetes After Renal Transplantation , 2011, Diabetes Care.

[20]  Kunam S Reddy,et al.  Hyperglycemia during the immediate period after kidney transplantation. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[21]  W. van Biesen,et al.  Posttransplantation Hypomagnesemia and Its Relation with Immunosuppression as Predictors of New‐Onset Diabetes after Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  Xin Gao,et al.  Influencing Factors of New-Onset Diabetes after a Renal Transplant and Their Effects on Complications and Survival Rate , 2014, PloS one.

[23]  T. Egeland,et al.  Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[25]  B. Kahan,et al.  New-onset diabetes after renal transplantation: diagnosis, incidence, risk factors, impact on outcomes, and novel implications. , 2011, Transplantation proceedings.

[26]  C. Mantzoros,et al.  20 years of leptin: role of leptin in human reproductive disorders. , 2014, The Journal of endocrinology.

[27]  P. Felig,et al.  Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. , 1973, The Journal of clinical investigation.

[28]  M. Salifu,et al.  Challenges in the diagnosis and management of new-onset diabetes after transplantation , 2005, Current diabetes reports.

[29]  J. Bradley,et al.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. , 2005, Critical reviews in oncology/hematology.

[30]  A. Olyaei,et al.  Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. , 2005, American journal of surgery.

[31]  F. Cosio,et al.  Cardiovascular Consequences of New-Onset Hyperglycemia After Kidney Transplantation , 2012, Transplantation.

[32]  Valerie Teal,et al.  Association of Metabolic Syndrome With Development of New-Onset Diabetes After Transplantation , 2010, Transplantation.

[33]  S. di Paolo,et al.  Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. , 2005, Journal of the American Society of Nephrology : JASN.

[34]  V. Deshpande,et al.  Autoimmune pancreatitis-related diabetes: quantitative analysis of endocrine islet cells and inflammatory infiltrate , 2010, Virchows Archiv.

[35]  R. Bloom,et al.  Transplant-associated hyperglycemia. , 2008, Transplantation reviews.

[36]  S. Dagogo-Jack,et al.  Approach to the patient with new-onset diabetes after transplant (NODAT). , 2011, The Journal of clinical endocrinology and metabolism.

[37]  I. Quesada,et al.  Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. , 2014, The Journal of endocrinology.

[38]  J. Gaynor,et al.  Multivariable risk of developing new onset diabetes after transplant—results from a single‐center study of 481 adult, primary kidney transplant recipients , 2015, Clinical transplantation.

[39]  M. Maitland,et al.  Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients , 2012, Clinical Cancer Research.

[40]  J. Chudek,et al.  Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. , 2012, Annals of transplantation.

[41]  M. Christiaans,et al.  Glucose metabolism before and after conversion from cyclosporine microemulsion to tacrolimus in stable renal recipients. , 2007, Nephrology, Dialysis and Transplantation.

[42]  F. Villamil,et al.  Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[43]  S. Bunnapradist,et al.  Pretransplant risk factors for new‐onset diabetes mellitus after transplant in pediatric liver transplant recipients , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[44]  F. Luan,et al.  Metabolic syndrome and new onset diabetes after transplantation in kidney transplant recipients , 2010, Clinical transplantation.

[45]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  P. Matias,et al.  Conversion to sirolimus in kidney-pancreas and pancreas transplantation. , 2008, Transplantation proceedings.

[47]  J. Dumortier,et al.  Risk factors for new‐onset diabetes mellitus following liver transplantation and impact of hepatitis c infection : An observational multicenter study , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[48]  G. Prasad,et al.  New-onset diabetes mellitus after kidney transplantation: Current status and future directions. , 2015, World journal of diabetes.

[49]  D. Mikhailidis,et al.  New-onset diabetes after transplantation , 2005, The Lancet.

[50]  Belinda Jim,et al.  Pathophysiologic and Treatment Strategies for Cardiovascular Disease in End-Stage Renal Disease and Kidney Transplantations , 2014, Cardiology in review.

[51]  M. Heymans,et al.  Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial. , 2014, European journal of endocrinology.

[52]  D. Elbourne,et al.  Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial , 2002, The Lancet.

[53]  P. Berloco,et al.  Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. , 2010, Transplantation proceedings.

[54]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[55]  R. Wait,et al.  Effects of cyclosporine on glucose metabolism. , 1989, Surgery.

[56]  S. Kesiraju,et al.  New onset of diabetes after transplantation - an overview of epidemiology, mechanism of development and diagnosis. , 2014, Transplant immunology.

[57]  H. Ortsäter,et al.  Glucocorticoids suppress GLP-1 secretion: possible contribution to their diabetogenic effects. , 2015, Clinical science.

[58]  A. Kitching,et al.  Four pediatric patients with autosomal recessive polycystic kidney disease developed new‐onset diabetes after renal transplantation , 2014, Pediatric transplantation.

[59]  M. Castagneto,et al.  Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. , 2006, Transplantation proceedings.

[60]  N. Azarpira,et al.  Association between E23K variant in KCNJ11 gene and new-onset diabetes after liver transplantation , 2014, Molecular Biology Reports.

[61]  Analysis of common type 2 diabetes mellitus genetic risk factors in new-onset diabetes after transplantation in kidney transplant patients medicated with tacrolimus , 2012, European Journal of Clinical Pharmacology.

[62]  J. Rovira,et al.  Mammalian target of rapamycin and diabetes: what does the current evidence tell us? , 2009, Transplantation proceedings.

[63]  F. Oppenheimer,et al.  Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. , 2007, Transplantation proceedings.

[64]  G. Klintmalm,et al.  12‐month follow‐up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[65]  A. Karelis,et al.  New-onset diabetes after transplantation: risk factors and clinical impact. , 2011, Diabetes & metabolism.

[66]  R. Pelletier,et al.  Steroid-Free Maintenance Immunosuppression With Rapamune and Low-Dose Neoral in Pancreas Transplant Recipients , 2007, Transplantation.

[67]  F. Cosio,et al.  Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. , 2001, Kidney international.

[68]  G. Klintmalm,et al.  RESULTS OF LIS2T, A MULTICENTER, RANDOMIZED STUDY COMPARING CYCLOSPORINE MICROEMULSION WITH C2 MONITORING AND TACROLIMUS WITH C0 MONITORING IN DE NOVO LIVER TRANSPLANTATION , 2004, Transplantation.

[69]  B. Kaplan,et al.  Single‐dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia , 2012, Clinical transplantation.

[70]  K. Wissing,et al.  Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment. , 2014, Transplantation reviews.

[71]  D. Renlund,et al.  A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[72]  V. Jha,et al.  Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[73]  N. Ohuchi,et al.  Pretransplant HbA1c Is a Useful Predictor for the Development of New-Onset Diabetes in Renal Transplant Recipients Receiving No or Low-Dose Erythropoietin , 2014, International journal of endocrinology.

[74]  L. Hilbrands,et al.  Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors. , 2013, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[75]  D. Mozaffarian,et al.  Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors , 2007, The Lancet.

[76]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  B. Fivush,et al.  Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients , 1996, Pediatric Nephrology.

[78]  K. Asonuma,et al.  Incidence and risk factors for new‐onset diabetes in living‐donor liver transplant recipients , 2013, Clinical transplantation.

[79]  A. Webster,et al.  Sirolimus is associated with new-onset diabetes in kidney transplant recipients. , 2008, Journal of the American Society of Nephrology : JASN.